November 24, 2025

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure

Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with...

The ASCO Post

November 21, 2025

Roswell Park Expands EDDY Program with Region’s First Mobile Screening Center for Breast and Prostate Cancer

Determined to make cancer screening accessible for people across Western New York, Roswell Park Comprehensive Cancer Center is proud to unveil the region’s most comprehensive mobile cancer screening initiative.

Roswell Park Comprehensive Cancer Center

November 19, 2025

Reflections of a Medical Oncologist: Empathy Matters in Caring for Patients With Cancer

“Someday you will be a doctor, Fazlur, and help people,” were the prophetic words of a mother to her son and the driving force behind the early quest of Fazlur Rahman, MD, to become a physician. Born ...

The ASCO Post

November 19, 2025

Preneoplastic and Neoplastic Small Lymphocytic Proliferations

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, ...

The ASCO Post

November 19, 2025

Curative Treatment After First-Line Immunotherapy Improves Survival in HCC

Curative treatment—resection, transplantation, and/or local ablation—following first-line immunotherapy is infrequently received, but when it was utilized, it significantly improved overall survival o...

The ASCO Post

November 17, 2025

Does Regular Opioid Use Increase Risks for Certain Cancers?

Regular pharmaceutical opioid use was found to be associated with an elevated risk for cancers previously associated with opium consumption, but not for other cancers, according to findings from a lar...

The ASCO Post

November 14, 2025

SABR May Be Comparable to Surgery for Early-Stage NSCLC

Stereotactic ablative radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), accordin...

The ASCO Post

November 13, 2025

Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma

In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was ...

The ASCO Post

November 12, 2025

Underlying Mechanisms of Chemoresistance in AML

Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cance...

The ASCO Post